Our study on the preclinical in vivo efficacy of Metavac®-RSV, an intranasal live-attenuated bivalent vaccine candidate against Respiratory Syncytial Virus and Human Metapneumovirus, has been published in Nature portfolio’s npj Vaccines.
This study reports challenge studies performed on mice model showing that intranasal immunisation with Metavac®-RSV fully protects animals against infections with wild type HMPV and RSV, the main sources of bronchiolitis and viral pneumonia in children and viral pneumonia in older adults, while inducing strong IgG and broad neutralizing antibody responses against heterologous RSV and HMPV strains. Our results validated the versatility of the Metavac® vaccine platform and suggest that Metavac®-RSV is a very promising mucosal bivalent LAV candidate to prevent pneumovirus-induced diseases.”
This innovation is issued from a very fruitful collaboration with Pr. Guy Boivin team LVMC at the Centre de Recherche du CHU de Québec – Université Laval, the Technology Research Platform Vinext, Pr Stéphane Paul team GIMAP at CIRI U1111, Dr Jean-François Elouet Team at INRAE and Vaxxel. The Proprietary recombinant Metavac® platform and derived monovalent and bivalent LAV vaccine candidates were licensed to Vaxxel, a spin-off created from our International Research Laboratory RESPIVIR France – Canada.